They keep talking about Sinovac trying to show Sinopharm also same but in fact is Sinopharm totally different and not approved in Malaysia. So how to use in Malaysia?
Wow sudah 6 hengget setengah, try harder promoter to chit the invester, lu kasi up apa lan chow punya vaksin news sini mari, kasi up bro, semua sudah untungggggg
@gohkimhock. You can have your own perception. Your perception not surely true. We don't know what will happen in the future. There is a probability, therefore there stands a hope.
Prospects for the financial period ending 31 March 2021 (“FPE 2021”)
The Group has identified the following main strategies to continue to grow its businesses:-
(a) Expansion into new bamboo concession and processing plant in Jingzhou, the PRC which has commenced operations in current financial quarter.
(b) Expansion of the Group’s flooring products with the launching of new series of bamboo flooring products.
(c) Enhancing the Group’s flooring products to focus more on ‘green’ strand woven products.
(d) Expansion of the Group’s product portfolio to include bamboo furniture marketed under the ‘KAR-ACE’ brand.
(e) Expansion into wood flooring products by promoting Classen’s products in the PRC through the collaboration with Classen GmbH as the Group is the exclusive distributor for Classen’s products in the PRC.
(f) Expansion of the Group’s presence by increasing the number of appointed dealers in its sales network and number of sales and marketing channels, for both its own and third party products.
(g) Identifying candidates to be the Group’s master agents/distributors in countries such as Malaysia, Australia and New Zealand.
(h) Intensifying efforts in the adoption and building out of a comprehensive omni-channel marketing strategy which is designed to cover all points of contact with existing and potential new customers. The Group is also cooperating closely with its dealers in implementing effective Online-to-Offline marketing and delivery channels. The online platforms include JD.com, Alibaba’s Taobao and various mini-programs offered by social media networks like WeChat.
Premised on the above, the Board is cautiously optimistic on the prospects of the Group for FPE 2021.
@18KHarmoni. He He. Saja nak tolong beri pencerahan sikit kepada issue yang dibangkitkan saudara kita . Prospek bisnis semasa kan buuuluuuh. Vaksin tu BONUS.
------------------- hlh1962 If next QR got revenue and profit then there is hope and not scam like Ikan bilis says. If still like last QR then something is quite wrong somewhere
Ingat kan aku sorang jer peradan Isu NPRA 1985 ni, tp sapa2 yg follow lama kanger ni, mesti perasan mamat ni, dah dpt komisen kaw2, now datang lagi jual taik minyak, pi mampus la
Nujum Pak Belalang memang pandai. Buat tekaan tanpa bukti pun. Seperti selalu, naysayer tanpa bukti.
Rugi saya tak dapat bersama NPRA1985 sebelum ini di dalam kaunter ini memandangkan saya amat baharu di sini.
Daripada fikir fasal NPRA1985, lebih baik fikir fasal kaunter ni saja.
Dapatkan maklumat untuk kenal pasti potensi pelaburan di dalam kaunter ini perlu lebih diberi perhatian., tak kiralah sebagai "day trader" ke, spekulator ke atau investor untuk jangka panjang.
Bagi yang berperanan sebagai Naysayer pun ada gunanya, mereka dapat keluarkan isu untuk dijawab oleh pihak lain.
Nampaknya betul-betul berpengaruh NPRA1985 sebelum ini. Lebih baik awak bincang fasal Kanger saja. Ada ke tak ada NPRA1985 di sini, bukan satu isu. Teruskan saja usaha awak untuk kutuk Kanger. Saya pun fikir elok juga kalau dapat harga yang lebih rendah nanti. 5.5 sen ke, 6 sen ke. He He
@18KHarmoni. Apa yang salah info nya. Semua info saya ada rujukannya ada report dan linknya. Saya berpandu kepada info saja. Kenapa nak marah. Sekadar cari info dan cuba kongsi. Percaya atau tidak fikir sendiri. TAYOR
Saya memang salesman. Bukan digaji oleh siapa-siapa. Konsep saya, bila dah beli saham dalam sesuatu saham walaupun sedikit, saya cuba "sale" kaunter tu jika mampu.
Cari maklumat dan ambil langkah untuk sebarkannya, termasuk buat artikel blog. Alasan mestilah nak cover kaunter yang kita masuk.
Awak tengok sejarah saya dalam kaunter lain, termasuk Nexgram dan Bornoil. Saya baru aktif dalam forum sejak tahun lepas sahaja.
Therefore, we are hoping that, sooner Kanger will be successful in securing their objective to be an approved Covid-19 vaccines distributor in Malaysia.
The Sinopharm / BIBP1 vaccine has been approved by WHO, whereas the Sinopharm / WIBP1 is still under its assessment process by WHO. Therefore, it’s better for Kanger to focus more on the currently approved vaccine by WHO, which is Sinopharm / BIBP1 for NPRA's approval. We, the investors of Kanger hope to receive some good news on its approval soon.
REMARKS: This article intended to report the current status of each MOUs and Agreements involving Kanger started from August 2020.
I wrote this article based on my research from www.bursamalaysia.com and information reported on the web. Any misreporting and emission of the information should not be my intention. All the information given is not for buy call or sell call purposes.
@BilisMasin. Setuju sepenuhnya dengan sebahagiannya, termasuk no. 1 dan 2.
Macam ni lah bagus. Baru gentleman.
But I want to differ for No. 3, 4 and 5. Just from my opinion and perspective only.
No. 3. - There are may MOUs and Agreements signed and reported by the company. - Some without any progress report. - There is agreement that has been reported as a contract which is starting to commence and executed, with its dead line also reported. - Some I think still in progressing state. Waiting for several requirements to be fulfilled before the MOUs or agreement can be executed, such as approvals from certain parties, internally or outside the company.
No. 5. - That's a kind of investments by the company. - Some companies did it. Some can make profit but some suffered losses.
No.5. - This kind of activities maybe played by insiders of the company or by sharks/operators or by the combination of the two parties. - But its probably played by the sharks/operators alone who are not linked with insiders. - If its involved sharks/operators without insiders play, WHAT CAN WE DO???
Started from August 2020, Kanger (0170) has signed several Memorandum of Understandings (MOUs) and agreement with several parties to start several business opportunities. The current status of the MOUs and agreements are as follows:
A Collaboration Agreement between Vegetta Champion Sdn. Bhd. and Kanger Ventures Sdn. Bhd. a wholly owned subsidiary of Kanger, relating to a construction contract at Genting Highlands with contract value RM478 million. Progress of the agreement:
Based on an announcement dated 2 March 2021. VCSB received a Letter of Intent dated 2 March 2021, whereby VCSB was appointed as the main contractor for foundation and main building works of a project. Kanger Ventures shall be responsible for the entire project management, financial and entire administration of the Project b. Based on an announcement dated 4 March 2021.
The Company announced that the Project is expected to commence in June 2021 and to be completed in 48 Months. Remarks: The construction project contract under this collaboration agreement will start on June 2021.
MOUs between Kanger and several parties, relating to the company’s efforts to secure as a distributor for Sinopharm Covid-19 vaccines in Malaysia. Progress of the MOUs:
Remarks: These MOUs is in progress and awaiting for NPRA’s approval for the Sinopharm Covid-19 vaccines before Kanger probably can execute the deal to import and distribute the vaccines in Malaysia.
A Conditional Sale Agreement (SSA) between Kanger and Vendors, relating to the proposed acquisition of 1,020,000 ordinary shares of Sung Master, representing 51.0% equity interest of Sung Master. Progress of the agreement:
Based on an announcement dated 26 April 2021. The company proposed acquisition of 1,020,000 ordinary shares of Sung Master, representing 51.0% equity interest of Sung Master ("Sale Shares") for a purchase consideration of RM94,789,436.00. The Purchase Consideration shall be satisfied via a combination of cash payment of RM51,999,999.62 whilst the remaining purchase consideration of RM42,789,436.38 shall be satisfied via the issuance of 713,157,273 new ordinary shares of Kanger at the issue price of RM0.06 per Kanger Share. Based on an announcement dated 12 May 2021. The company announced that the listing application for the Proposals has been submitted to Bursa Malaysia Securities Berhad on 12 May 2021. Remarks: This agreement is in progress and awaiting for approval from the authority’s approval and the completion of the proposed Right Issue (RI) with warrants exercises.
A Conditional Sale and Purchase Agreement (SPA) between Kanger Ventures Sdn Bhd and Aset Kayamas Sdn Bhd, relating to the proposed acquisition of serviced apartments located @ Genting Highlands, Bentong, Pahang. Progress of the agreement:
Based on an announcement dated 24 February 2021. The company announced the acquisition proposal by Kanger Ventures Sdn Bhd , a wholly-owned subsidiary of Kanger, of 126 units of proposed serviced apartments located on the 30th to 45th floors of Tower A, Antara @ Genting Highlands, Bentong, Pahang from the developer, namely Aset Kayamas Sdn Bhd for a total purchase consideration of RM142,870,000 to be satisfied entirely via cash.
Based on an announcement dated 19 April 2021. The company announced that the listing application pursuant to the Proposals has been submitted to Bursa Malaysia Securities Berhad on 19 April 2021.
Based on an announcement dated 26 April 2021. The company announced that the Board had on 26 April 2021 ("Price-Fixing Date") resolved to fix the issue price of the Rights Shares at RM0.06 per Rights Share ("Issue Price").
Based on an announcement dated 2 June 2021. The company announced that the Bursa Securities vide its letter dated 2 June 2021, resolved to approved the following:- Admission to the Official List and listing and quotation of up to 2,861,936,149 Warrants B to be issued pursuant to the Proposed Rights Issue with Warrants; ii. Listing and quotation of:-
Up to 2,861,936,149 new Kanger Shares to be issued pursuant to the Proposed Rights Issue with Warrants;
Remarks: This agreement in progress and awaiting for the completion of the proposed Right Issue (RI) with warrants exercises.
A Collaboration Agreement between Kanger Ventures and Multiple Novation, relating to a multiple constructions works. Progress of the agreement:
a. Based on an announcement dated 15 January 2021
The Board of Directors of Kanger International wishes to announce that its wholly-owned subsidiary, Kanger Ventures Sdn Bhd , had on 15 January 2021 entered into the following Collaboration Agreements.
a) Qbeez Holdings Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 6th July 2018 for construction of main building works of the project of development of three (3) blocks of affordable apartment on Lot 52957, Jalan Desa, Taman Desa, Mukim Kuala Lumpur, Wilayah Persekutuan (“Qbeez Project 1”);
b) Qbeez Holdings Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 28th December 2018 for construction of building and external works for the project of development two (2) blocks apartment on PT 15659, Jalan Indrahana 3, Mukim Petaling, Kuala Lumpur, Wilayah Persekutuan (“Qbeez Project 2”);
c) Lead Pinnacle Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 28th October 2019 for construction of piling and foundation works of the project of construction of a temporary gallery on PT 23923, (H.S.(D) 18603) Genting Highlands, Mukim Bentong, Daerah Bentong, Negeri Pahang (“Lead Project 1”);
d) Lead Pinnacle Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 7th July 2020 for construction of foundation and main building works for the project of a mixed development of two (2) blocks of service apartment on PT 23923, (H.S.(D) 18603) Genting Highlands, Mukim Bentong, Daerah Bentong, Negeri Pahang (“Lead Project 2”);
e) Deseo Engineering Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 13th April 2018 for construction of main building works for the project of a development of two (2) blocks of affordable apartments and two (2) blocks of apartment on Lot 55121, Jalan Jujur, Bandar Tun Razak, Cheras, Kuala Lumpur (“Deseo Project”);
f) Enduring Power Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 1st June 2019 for construction of main building works for the project of a development of two (2) blocks of service apartment on Lot 1351 & 1377, Jalan Padang/Jalan Padang Walter Grenier dan sebahagian simpanan Jalan, Seksyen 67, Bukit Bintang, Bandar Kuala Lumpur (“Enduring Project”).
Any approval required from the relevant authority and shareholders in a general meeting of the Company to undertake this collaboration herein contemplated; The Parties shall fulfill the above conditions within 90 (ninety) days from the date of these agreements or such extended date as shall be mutually agreed in writing by the Parties (Cut-Off Date).
Remarks: No further announcement on the progress of this Collaboration Agreement yet by to date.
A Head of Agreement between Kanger and Constellation Holdings Ltd, Dubai regarding the setting up of medical examination gloves manufacturing operations in Malaysia. Progress of the agreement:
Announcement on 11 August 2020. The company has received a formal Expression of Interest letter (“EOI”) dated 9 August 2020 from Constellation Holdings Limited, Dubai (“Constellation”) for collaboration in the setting up of medical examination gloves operations in Malaysia. Announcement on 14 August 2020. The company had, on 13 August 2020 entered into a heads of agreement with Constellation Holdings Limited. Kanger is setting up a glove manufacturing plant in Ijok, Selangor for about RM77 million. Kanger has incorporated a wholly-owned subsidiary, Kanger Glove Manufacturing Sdn Bhd, which will acquire around five acres in Ijok for RM6.8 million. Kanger Glove would spend RM70 million to build the plant and install up to eight production lines to produce medical, surgical and/or nitrile glove.
Announcement on 21 August 2020. The Company provided additional information pursuant to the queries by BURSA. The company need to apply for the relevant regulatory approvals for setting up the factory. Remarks: No further announcement or report on the progress of this medical examination gloves manufacturing operations can be retrieved by the writer yet by to date.
** DISCLAIMER: I wrote this article based on my research from www.bursamalaysia.com and information reported on the web. Any misreporting and emission of the information should not be my intention. All the information given is not for buy call or sell call purposes.
RIGHTS ISSUE WITH WARRANTS APPROVED! TIME TO FLY SOON?!
Seasoned investors that are familiar with corporate exercise would definitely be no stranger to rights issue. But for new investors, rights issue is commonly a way for listed companies to raise additional capital from shareholders – sometimes it also comes with a sweetener, warrant.
How impactful is warrant on the share price? Just take a look at these few companies share price after bonus issue or rights issue that comes with warrant.
Of course, there are plenty more examples where companies that issued free warrants might spike up. But why is that so?
Warrant – as a financial derivative which carries the ability to allow its holder to have the right but not obligated to convert it into mother share, often seen as an opportunity to arbitrage. It is an advanced technique that often used by seasoned investors but to put it in plain English, some big holders of warrant might “push” the mother share price to increase the attractiveness in warrant due to the conversion gap and the arbitrage opportunity.
However, Kanger International Berhad (KLSE: KANGER) – the recent darling of vaccine theme play had finally gotten their approval from Bursa for the rights issue that comes along with the warrant sweetener.
How do we know for sure KANGER might fly anytime soon? To answer this question, we must study the price movement pattern of the company.
As you can see, the company had a downturn in share price and momentum since the vaccine market was slammed hard by the government. But what we could tell from the chart is that there is an attempt to breakout on 28th May 2021. What could possibly trigger the buying momentum?
After going around several forums and platforms, I noticed that there are already rumours being spread on KANGER’s rights issue shall be approved at anytime soon. Perhaps this spiked the buying interest – but unfortunately, the company only announced the good news on yesterday, hence investors might have got in too early.
Nevertheless, with the approval for warrants, I’m sure that KANGER will continue to fly once operator had finished the accumulation of shares – which they already did since 2019 to 2020 and washed most new investors off KANGER by now.
From technical analysis + corporate news standpoint, we could begin our execution on the trade. The for-sure support level for the company is at 6.0 cents level. And the most recent resistance of the company would be at 11.5 cents and 15.0 cents, respectively. This represents a potential downside risk of 20.0%, and for the upside, that would be between 53.3% and 100.0%, representing a risk-to-reward ratio of 2.6 times to 5.0 times!
On the back of years of my trading experience, KANGER will definitely ride on the positive news and depart soon. Do not miss out the ride on this company!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
deepseavalue
66 posts
Posted by deepseavalue > 2021-06-08 14:52 | Report Abuse
strong support at 0.06, thanks for selling so I can grab cheap